Status:
COMPLETED
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
Lead Sponsor:
AstraZeneca
Conditions:
GERD
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.
Eligibility Criteria
Inclusion
- Subjects who seek medical advice in primary care for symptoms thought to be GERD related (GERD is a condition which develops when the reflux of stomach content causes troublesome symptoms and / or complications).
Exclusion
- Subjects with any clinical GERD treatment (PPI, H2-receptor antagonists) within the last 3 months prior to Visit 1.
- A history of severe esophagitis or known other complications, with alarm symptoms
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
3029 Patients enrolled
Trial Details
Trial ID
NCT00444275
Start Date
March 1 2007
End Date
October 1 2008
Last Update
December 11 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Rouen, France